We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

149 hedge funds and large institutions have $342M invested in iShares US Pharmaceuticals ETF in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 44 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

157% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 7

7% more funds holding

Funds holding: 139 → 149 (+10)

5% more capital invested

Capital invested by funds: $326M → $342M (+$16.8M)

0.52% less ownership

Funds ownership: 58.79% → 58.27% (-0.52%)

27% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 44

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $297K

Holders
149
Holders Change
+10
Holders Change %
+7.19%
% of All Funds
1.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
32
Reduced
44
Closed
7
Calls
–
Puts
$297K
Net Calls
-$297K
Net Calls Change
-$297K

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$932K
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$759K
3
Rockefeller Capital Management
Rockefeller Capital Management
New York
+$736K
4
Goldman Sachs
Goldman Sachs
New York
+$503K
5
Corient Private Wealth
Corient Private Wealth
Florida
+$435K

Top Sellers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$6.9M
2
Fisher Asset Management
Fisher Asset Management
Washington
-$6.23M
3
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans
Minnesota
-$2.47M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.17M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
VFG
76
V2 Financial group
Illinois
$239K – – –
KWA
77
Kingswood Wealth Advisors
California
$225K – – –
SFI
78
SPC Financial Inc
Maryland
$224K – – –
MCM
79
Manchester Capital Management
Vermont
$218K – – –
HI
80
Hudock Inc
Pennsylvania
$212K +$201K +2,920 New
EH
81
Equitable Holdings
New York
$209K +$198K +2,877 New
SWM
82
Spire Wealth Management
Virginia
$207K -$82.8K -1,200 -30%
YDMI
83
Y.D. More Investments
Israel
$196K – – –
BLC
84
Brown, Lisle/Cummings
Rhode Island
$172K – – –
WANY
85
Wealthspire Advisors (New York)
New York
$172K +$164K +2,372 New
Comerica Bank
86
Comerica Bank
Texas
$151K -$2.76K -40 -2%
Northwestern Mutual Wealth Management
87
Northwestern Mutual Wealth Management
Wisconsin
$144K +$6K +87 +5%
AF
88
Allworth Financial
California
$104K -$7.45K -108 -7%
BGAI
89
Bruce G. Allen Investments
Colorado
$102K +$414 +6 +0.4%
AAS
90
Ameritas Advisory Services
Nebraska
$88.5K -$93.4K -1,354 -53%
NA
91
NewEdge Advisors
Louisiana
$87.9K – – –
Fifth Third Bancorp
92
Fifth Third Bancorp
Ohio
$84.7K – – –
RIA
93
Realta Investment Advisors
Delaware
$65.3K – – –
VWM
94
Valley Wealth Managers
New Jersey
$65.3K – – –
RIL
95
Rothschild Investment LLC
Illinois
$61.4K +$31.5K +456 +117%
SS
96
Sunbelt Securities
Texas
$61K -$197K -2,862 -77%
CI
97
CX Institutional
Indiana
$58K +$53.3K +773 +2,666%
GWM
98
Geneos Wealth Management
Colorado
$57.9K – – –
IA
99
IFP Advisors
Florida
$51.1K – – –
TWC
100
TD Waterhouse Canada
Ontario, Canada
$48.3K – – –
2 3
4
5 6

IHE Hedge Fund Activity: Q3 2025 in Review

149 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2025, worth a combined $342M — up 5.2% from $326M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new IHE positions and 7 closed out — a net gain of 11 holders — while 32 added to existing stakes and 44 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $932K. The largest seller was BNP Paribas Financial Markets, cutting an estimated $6.9M.

  • 149 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2025, up from 139 in Q2 2025.
  • Funds reported $342M of iShares US Pharmaceuticals ETF stock for Q3 2025, up 5.2% quarter-over-quarter.
  • 18 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2025 and 7 closed out, a net change of +11 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q3 2025 was Jane Street, an estimated $932K added.
  • The largest iShares US Pharmaceuticals ETF seller in Q3 2025 was BNP Paribas Financial Markets, an estimated $6.9M sold.

Based on aggregated 13F filings for Q3 2025.